Simpson–Golabi–Behmel Syndrome Type 1: Disease Characteristics Report

Executive summary

Simpson–Golabi–Behmel syndrome type 1 (SGBS1) is a congenital X-linked overgrowth and multiple-malformation syndrome caused primarily by germline loss-of-function variants in GPC3, which encodes the cell-surface heparan-sulfate proteoglycan glypican-3. Its major manifestations are prenatal and postnatal overgrowth, macrocephaly, organomegaly, characteristic craniofacial and skeletal findings, congenital cardiac/genitourinary/gastrointestinal abnormalities, variable neurodevelopmental impairment, and predisposition to embryonal tumors—especially Wilms tumor and hepatic tumors. Expression is usually greatest in hemizygous males, but symptomatic heterozygous females occur. Prevalence and incidence remain unknown, reflecting extreme rarity, variable expression, early lethality, and probable underdiagnosis. There is no disease-modifying treatment; current practice comprises molecular diagnosis, multidisciplinary supportive care, tumor and cardiac surveillance, and reproductive counseling. (vuillaume2019cugcforsimpsongolabibehmel pages 2-4, vuillaume2019cugcforsimpsongolabibehmel pages 4-5, vuillaume2019cugcforsimpsongolabibehmel pages 1-2)

The principal quantitative genetic dataset available in the retrieved literature comprised 86 distinct GPC3 variants in 120 unrelated families and 152 affected males. Large deletions represented 34.9%, frameshift variants 24.4%, nonsense variants 16.3%, missense variants 8.1%, large duplications 8.1%, splice-site variants 4.7%, translocations 2.3%, and in-frame indels 1.2%. (vuillaume2019cugcforsimpsongolabibehmel pages 1-2)

Table: This table condenses the highest-yield disease knowledge-base fields for Simpson-Golabi-Behmel syndrome type 1, including identifiers, genetics, phenotype, mechanism, management, and evidence gaps. It is aligned to the gathered evidence and highlights the key quantitative variant data needed for structured curation.

1. Disease information

Definition and identifiers

• Preferred name: Simpson–Golabi–Behmel syndrome type 1
• Common synonyms: Simpson–Golabi–Behmel syndrome; SGBS; SGBS1; Simpson dysmorphia syndrome; Golabi–Rosen syndrome; bulldog syndrome. The last three are historical terms and are less suitable as preferred labels.
• MONDO: MONDO:0020602
• OMIM phenotype: 312870
• Causal-gene OMIM entry: GPC3, 300037
• Gene: GPC3, glypican 3; Ensembl ENSG00000147257; chromosome Xq26.3. Open Targets identifies GPC3 as the sole associated target and assigns a target–disease association score of 0.767, driven predominantly by human genetic evidence. (OpenTargets Search: Simpson-Golabi-Behmel syndrome type 1-GPC3)
• Orphanet: SGBS is represented as a rare genetic overgrowth syndrome, although an exact Orpha identifier was not verified in the retrieved full-text evidence and should be validated directly before database import.
• ICD: No highly specific ICD-10-CM code was verified. It is generally coded under congenital malformation or overgrowth-syndrome categories. ICD-11 mapping should likewise be verified against the current release rather than inferred.
• MeSH: No disease-specific MeSH descriptor was established in the retrieved evidence; indexing may use broader headings such as congenital abnormalities, overgrowth, or X-linked genetic diseases.

The evidence base is aggregated disease-level knowledge derived from published families, case series, mutation compilations, clinical-utility guidance, and model systems—not a representative EHR cohort. Consequently, phenotype frequencies are vulnerable to ascertainment and publication bias. The 2019 clinical-utility guideline describes presentation as typically evident from birth. (vuillaume2019cugcforsimpsongolabibehmel pages 2-4, vuillaume2019cugcforsimpsongolabibehmel pages 1-2)

2. Etiology, risk factors, protective factors, and environment

Causal factor

The primary cause is a germline loss-of-function alteration of GPC3. Hemizygous pathogenic variants cause the classical phenotype in males. Most variants truncate the protein or delete one or more exons; pathogenic structural rearrangements also occur. The reviewed gene contains eight exons and produces an approximately 2.3-kb transcript. (vuillaume2019cugcforsimpsongolabibehmel pages 1-2, vuillaume2018mutationupdatefor pages 1-2)

Genetic risk

A pathogenic familial GPC3 allele is the principal risk factor. Under X-linked transmission, a heterozygous mother has, for each pregnancy, a 50% probability of transmitting the altered allele; sons who inherit it are generally affected, while daughters who inherit it are heterozygous and may be asymptomatic or variably affected. Male-to-male transmission does not occur. The mutation update found only 18% of reported variants to be de novo, indicating that familial transmission is important, although this proportion is subject to referral bias. (vuillaume2019cugcforsimpsongolabibehmel pages 2-4, vuillaume2018mutationupdatefor pages 13-14)

Female expression is plausibly influenced by skewed X-chromosome inactivation and variant/rearrangement context, but no validated modifier gene or clinically actionable modifier allele was established in the retrieved evidence. “Complete penetrance in males” is reported in the clinical-utility guideline; expressivity is nevertheless markedly variable. (vuillaume2019cugcforsimpsongolabibehmel pages 2-4)

Environmental, infectious, and lifestyle factors

No toxin, infection, diet, smoking exposure, occupation, or lifestyle factor is established as a cause of SGBS1. Maternal or postnatal environment may alter general outcomes of congenital heart disease, hypoglycemia, respiratory compromise, or cancer, but these are nonspecific modifiers rather than etiologic factors. No replicated gene–environment interaction or protective environmental factor has been demonstrated.

Protective factors

No genetic protective variant, dietary intervention, medication, or exposure is known to prevent expression after inheritance of a pathogenic GPC3 variant. Early recognition and surveillance are risk-mitigating clinical measures, not biological protection against disease onset.

3. Phenotypes

SGBS1 begins during fetal development. Severity ranges from mild dysmorphism and learning difficulty to lethal multisystem malformations. Reliable percentages for most individual manifestations were not recoverable from the available evidence; qualitative frequencies are therefore preferable to invented precision. Core features compiled across the mutation review and clinical guideline include the following. (vuillaume2019cugcforsimpsongolabibehmel pages 1-2, vuillaume2018mutationupdatefor pages 1-2)

• Prenatal/postnatal overgrowth: congenital physical sign; often fetal macrosomia followed by childhood overgrowth; variable persistence. Suggested HPO: HP:0001524 Fetal macrosomia, HP:0001548 Overgrowth.
• Macrocephaly: congenital or early-childhood sign, usually stable relative to growth. HP:0000256.
• Macroglossia: congenital physical manifestation that can impair feeding or airway function. HP:0000158.
• Organomegaly/visceromegaly: congenital sign involving liver, kidney, spleen, or other viscera. HP:0003270 Organomegaly.
• Characteristic/coarse facies: broad or coarse face, large mouth, broad nose, and related dysmorphism; usually recognizable from infancy. HP:0000280 Coarse facial features.
• Supernumerary nipples: congenital, generally stable and medically minor. HP:0002558.
• Skeletal/limb abnormalities: broad hands, short or broad distal phalanges, syndactyly or polydactyly, rib/vertebral abnormalities, and pectus deformity; congenital and generally nonprogressive. Suggested terms: HP:0010442 Polydactyly, HP:0001159 Syndactyly, HP:0000767 Pectus excavatum, HP:0000924 Abnormality of the skeletal system.
• Congenital heart disease and electrical disease: structural lesions, cardiomyopathy, conduction abnormalities, or arrhythmias may occur. Severity ranges from incidental to life-threatening. HP:0001627, HP:0011675 Arrhythmia, HP:0001638 Cardiomyopathy. Regular cardiac follow-up is recommended. (vuillaume2019cugcforsimpsongolabibehmel pages 4-5)
• Diaphragmatic hernia and pulmonary hypoplasia: uncommon but major determinants of neonatal mortality. HP:0000776, HP:0002089. The clinical guideline identifies congenital malformations, especially diaphragmatic hernia, as causes of early life-threatening disease. (vuillaume2019cugcforsimpsongolabibehmel pages 4-5)
• Genitourinary abnormalities: cryptorchidism, hypospadias, renal anomalies, and occasionally more extensive disorders of sex development. HP:0000028, HP:0000047, HP:0000077.
• Gastrointestinal abnormalities: congenital structural defects, including anorectal anomalies, may occur. HP:0002027 Abnormality of the gastrointestinal tract.
• Neonatal hypoglycemia: laboratory abnormality requiring prompt treatment. HP:0001943. (vuillaume2019cugcforsimpsongolabibehmel pages 4-5)
• Developmental delay, learning difficulty, or intellectual disability: variable, usually mild-to-moderate when present; may impair education, communication, independence, and adult employment. HP:0001263, HP:0001328, HP:0001249. (vuillaume2019cugcforsimpsongolabibehmel pages 4-5)
• Embryonal tumors: primarily Wilms tumor and liver tumors; gonadoblastoma is also a surveillance concern. HP:0002669 Neoplasm. (vuillaume2019cugcforsimpsongolabibehmel pages 4-5, vuillaume2018mutationupdatefor pages 1-2)

No validated SGBS1-specific EQ-5D, SF-36, PROMIS, or disease-specific quality-of-life study was identified. Quality-of-life burden is therefore inferred from congenital surgery, cardiac disease, developmental disability, cancer surveillance, and family reproductive burden rather than measured with standardized instruments.

4. Genetic and molecular information

GPC3 encodes an approximately 70-kDa glycosylphosphatidylinositol-anchored heparan-sulfate proteoglycan located on the outer plasma membrane. The disease mechanism is predominantly loss of function, not gain of function or dominant negativity. Disease-associated changes include whole/partial-gene deletions, exon-level deletions or duplications, frameshift, nonsense, canonical splice, missense, in-frame indel, and chromosomal rearrangement variants. (vuillaume2018mutationupdatefor pages 1-2, vuillaume2019cugcforsimpsongolabibehmel pages 1-2)

The observed distribution—34.9% large deletions, 24.4% frameshift, and 16.3% nonsense—strongly supports haploinsufficiency/absence of functional protein as the central mechanism. The 86 reported variants span the coding region and include complex rearrangements. (vuillaume2018mutationupdatefor pages 1-2, vuillaume2019cugcforsimpsongolabibehmel pages 1-2)

Variants are constitutional/germline. A tumor arising in an affected person can acquire additional somatic alterations, but a somatic GPC3 variant alone is not equivalent to inherited SGBS1. Pathogenic alleles are expected to be absent or extremely rare from reference populations; however, exact gnomAD allele frequencies must be checked per variant. No single recurrent founder allele or robust population-specific carrier frequency was established.

Large Xq26 rearrangements may encompass neighboring genes, potentially producing a contiguous-gene phenotype. Copy-number analysis is consequently essential. No reproducible GPC3-associated DNA-methylation “episignature,” histone abnormality, or clinically validated epigenetic diagnostic test was found. Likewise, no established human modifier gene explains inter- or intrafamilial variation.

5. Environmental information

SGBS1 is not an environmentally acquired, infectious, occupational, or lifestyle-mediated disease. There is no zoonotic, transmissible, or exposure-related component. Standard avoidance of tobacco, alcohol, radiation, and toxins during pregnancy remains general prenatal-health advice but is not specific prevention for GPC3-associated disease.

6. Mechanism and pathophysiology

Ordered causal chain

1. A germline hemizygous GPC3 loss-of-function variant leads to absent or deficient functional glypican-3 at the external plasma membrane.
2. Loss of this heparan-sulfate co-receptor leads to abnormal extracellular presentation, sequestration, or receptor engagement of developmental morphogens.
3. This results in dysregulated Hedgehog, WNT, FGF, and BMP signaling; Hedgehog hyperactivation with increased Sonic and Indian Hedgehog proteins is demonstrated in Gpc3-null models, whereas the exact direction and magnitude of each pathway in every human tissue remain context-dependent. (vuillaume2018mutationupdatefor pages 1-2, vuillaume2018mutationupdatefor pages 13-14)
4. Dysregulated morphogen signaling leads to abnormal control of proliferation, apoptosis, polarity, differentiation, and organ patterning during embryogenesis.
5. Excess developmental growth and disturbed patterning result in fetal/postnatal overgrowth, macrocephaly, visceromegaly, skeletal/limb abnormalities, and cardiac, renal, pulmonary, gastrointestinal, and genital malformations.
6. Branch: severe structural defects lead to respiratory or cardiac compromise and can result in perinatal death.
7. Branch: disturbed developmental growth restraint is inferred to increase susceptibility to embryonal neoplasia, resulting particularly in Wilms tumor and hepatic tumors; the complete tumor-initiating sequence in human SGBS1 tissues remains incompletely demonstrated.
8. Altered nervous-system development is inferred to contribute to variable developmental delay and learning disability.

Upstream events are GPC3 deficiency and morphogen dysregulation; downstream events are altered cellular behavior, malformed organs, overgrowth, and tumor susceptibility. Appropriate GO annotations include GO:0007224 smoothened signaling pathway, GO:0060070 canonical Wnt signaling pathway, GO:0008543 fibroblast growth factor receptor signaling pathway, GO:0030509 BMP signaling pathway, GO:0008283 cell population proliferation, GO:0048513 animal organ development, and GO:0007275 multicellular organism development.

Relevant cell classes are broad rather than a single targeted lineage: embryonic mesenchymal cells (CL:0000134 mesenchymal cell), chondrocytes (CL:0000138), cardiomyocytes (CL:0000746), renal epithelial/nephron progenitor lineages, hepatoblasts, pulmonary epithelial cells, placental trophoblasts, and neural progenitors. These cell assignments are biologically plausible and supported principally by affected-organ and mouse-model phenotypes, not by a definitive human single-cell atlas.

No consistent SGBS1 metabolomic, lipidomic, proteomic, spatial-transcriptomic, or patient single-cell signature has been clinically validated. No SGBS1-specific CRISPR screen, organoid diagnostic assay, or multi-omics classifier was identified. These remain research opportunities rather than current applications.

7. Anatomical structures affected

Primary systems include:

• Whole-body growth axis and placenta: placentomegaly and fetal overgrowth; UBERON suggestions UBERON:0001987 placenta, UBERON:0000468 multicellular organism.
• Craniofacial complex and tongue: UBERON:0007811 cranium, UBERON:0001723 tongue.
• Skeleton and limbs: axial skeleton, ribs, vertebrae, hands, feet, digits; UBERON:0004288 skeleton of hand, UBERON:0001464 skeletal system.
• Heart: structural myocardium and cardiac conduction system; UBERON:0000948 heart.
• Kidneys and urinary tract: UBERON:0002113 kidney.
• Liver and abdominal viscera: UBERON:0002107 liver.
• Lungs and diaphragm: UBERON:0002048 lung, UBERON:0001103 diaphragm.
• Gastrointestinal tract: UBERON:0005409 alimentary part of gastrointestinal system.
• Testes and external genitalia: UBERON:0000473 testis.
• Central nervous system: developmental involvement underlying variable cognition; UBERON:0000955 brain.

At the subcellular level, the primary compartment is the external side of the plasma membrane/cell surface, where GPI-anchored glypican-3 regulates extracellular morphogens. Suggested GO Cellular Component annotations are GO:0009986 cell surface, GO:0005886 plasma membrane, and GO:0031225 anchored component of membrane. There is no characteristic lateralization; anomalies may be bilateral, unilateral, or asymmetric according to organ and individual.

8. Temporal development

Onset is prenatal, with fetal macrosomia, enlarged organs, increased nuchal thickness, polyhydramnios, or structural malformations sometimes detectable by ultrasound. Ultrasound findings are not pathognomonic, and many diagnoses are made postnatally. Clinically recognizable overgrowth and dysmorphism are usually present at birth. (vuillaume2019cugcforsimpsongolabibehmel pages 2-4, vuillaume2019cugcforsimpsongolabibehmel pages 1-2)

There is no accepted formal staging system. A practical course is:

1. Prenatal/perinatal phase: overgrowth and congenital malformations; highest risk from diaphragmatic hernia, pulmonary hypoplasia, severe heart disease, and hypoglycemia.
2. Infancy/childhood: surgical treatment of malformations, developmental assessment, growth monitoring, and intensive embryonal-tumor surveillance.
3. Later childhood/adolescence: learning, speech, orthopedic, cardiac, and psychosocial needs; some childhood tumor risks decline with age.
4. Adulthood: congenital traits persist; available natural-history data are sparse, but many less severely affected patients survive with near-normal life expectancy. Cardiac and individual tumor-related follow-up remains clinically relevant. (vuillaume2019cugcforsimpsongolabibehmel pages 4-5)

The condition is lifelong rather than episodic or remitting. Structural anomalies do not spontaneously remit, although treated hypoglycemia or surgically corrected lesions can resolve. The prenatal period and first years of life are the most important intervention windows.

9. Inheritance and population

Inheritance is X-linked, conventionally described as X-linked recessive, although clinically affected heterozygous females demonstrate that the label does not imply absolute female nonpenetrance. Male penetrance is reported as complete, while severity is highly variable. Female carriers are usually asymptomatic or mildly affected. (vuillaume2019cugcforsimpsongolabibehmel pages 2-4, vuillaume2019cugcforsimpsongolabibehmel pages 1-2)

No genetic anticipation is known. Maternal germline mosaicism is biologically possible and should be considered after an apparently de novo result, although its frequency is unknown. Consanguinity is not a major determinant of this X-linked condition. No well-established founder effect, ethnic enrichment, regional endemicity, or reliable carrier frequency has been demonstrated.

Prevalence and incidence are unknown. The literature review identified only 152 affected males across 120 unrelated families, illustrating rarity but not population prevalence. SGBS1 occurs across geographic and ancestral groups. The observed sex ratio is strongly male-biased for clinically recognized classical disease, but this is not evidence that females cannot be affected. (vuillaume2019cugcforsimpsongolabibehmel pages 1-2)

10. Diagnostics

Clinical evaluation

Evaluation should document prenatal and postnatal growth, head circumference, dysmorphism, macroglossia, nipples, hands/feet, chest and spine, genitalia, developmental status, and family history. Initial investigations commonly include glucose assessment in neonates, echocardiography and ECG, abdominal/renal ultrasound, and targeted imaging or functional testing based on malformations. There is no diagnostic serum enzyme assay or validated circulating biomarker.

Genetic-testing strategy

1. GPC3 sequencing should detect small coding and splice-region variants.
2. Deletion/duplication analysis by MLPA, exon-level array, or validated NGS copy-number analysis is essential because large deletions are the largest reported variant class.
3. If negative but suspicion remains high, use a comprehensive overgrowth/malformation panel or exome/genome sequencing with copy-number and structural-variant calling.
4. Chromosomal microarray is useful for larger Xq26 deletions/duplications and possible contiguous-gene syndromes.
5. Genome sequencing may resolve complex rearrangements or intronic/regulatory variants missed by conventional tests.
6. Confirm clinically important variants and test the mother and other at-risk relatives for segregation and counseling.

The clinical-utility guideline reports nearly 100% analytical sensitivity and specificity for detectable coding-exon/flanking-intron variants, but this must not be misread as 100% overall diagnostic yield because promoter, deep-intronic, mosaic, and difficult structural variants can escape a particular assay. PCR, Sanger sequencing, and MLPA were the established methods in the reviewed series. (vuillaume2019cugcforsimpsongolabibehmel pages 2-4, vuillaume2019cugcforsimpsongolabibehmel pages 1-2)

Karyotyping and FISH are not preferred first-line tests but may characterize visible or targeted rearrangements. Mitochondrial-DNA and repeat-expansion testing are not relevant. RNA sequencing may help resolve a suspected splice variant, but it is not routine. There is no established diagnostic proteomic, metabolomic, epigenomic, or liquid-biopsy assay.

Differential diagnosis

The principal differential is Beckwith–Wiedemann spectrum, which shares macrosomia, macroglossia, visceromegaly, neonatal hypoglycemia, and embryonal tumors. Distinguishing features include the X-linked pedigree and GPC3 variant in SGBS1 versus 11p15 imprinting abnormalities or CDKN1C variants in Beckwith–Wiedemann spectrum. Other considerations include Perlman syndrome, Sotos syndrome, Weaver syndrome, Malan syndrome, PI3K-AKT-related overgrowth, and nonsyndromic familial tall stature. The clinical guideline explicitly identifies Beckwith–Wiedemann syndrome as the major differential. (vuillaume2019cugcforsimpsongolabibehmel pages 2-4)

There is no population newborn screen. Appropriate screening is phenotype-triggered testing and cascade testing in an identified family.

11. Outcome and prognosis

Prognosis is heterogeneous. Severe congenital diaphragmatic, pulmonary, cardiac, or other malformations can cause fetal, neonatal, or infant death. In survivors without severe malformations, prognosis is often relatively favorable and life expectancy may be normal, although cardiac complications, tumors, developmental disability, and repeated procedures create substantial morbidity. (vuillaume2019cugcforsimpsongolabibehmel pages 2-4, vuillaume2019cugcforsimpsongolabibehmel pages 4-5)

No reliable 5-year or 10-year survival estimate, disease-specific mortality rate, or validated prognostic calculator exists. Important adverse prognostic factors are severe congenital malformations, respiratory compromise, major heart disease or arrhythmia, malignant tumor development, and more substantial neurodevelopmental impairment. No molecular prognostic biomarker beyond broad genotype/structural-variant context has been validated.

Recovery from the underlying genetic syndrome is not expected. Individual complications—hypoglycemia, hernia, cryptorchidism, congenital cardiac lesions, orthopedic problems, or cancer—may be successfully treated. No standardized long-term disability or quality-of-life dataset was identified.

12. Treatment and real-world implementation

There is no approved etiologic pharmacotherapy, gene therapy, RNA therapy, cell therapy, or GPC3-replacement treatment. Care is individualized and multidisciplinary. (vuillaume2019cugcforsimpsongolabibehmel pages 4-5)

• Treat neonatal hypoglycemia promptly with glucose-based neonatal protocols. Suggested NCIt concepts: Supportive Care, Glucose Administration.
• Stabilize airway and respiration; repair diaphragmatic hernia and other structural defects when indicated. NCIt: Surgical Procedure.
• Manage congenital heart disease, cardiomyopathy, conduction disease, and arrhythmia according to pediatric cardiology standards; maintain longitudinal ECG/echocardiographic follow-up. (vuillaume2019cugcforsimpsongolabibehmel pages 4-5)
• Correct cryptorchidism, hypospadias, gastrointestinal anomalies, skeletal deformity, and feeding/airway problems when clinically indicated.
• Provide physical, occupational, speech-language, educational, and neuropsychological support. Moderate or mild psychomotor delay and learning difficulty may remain functionally important in adulthood. (vuillaume2019cugcforsimpsongolabibehmel pages 4-5)
• Coordinate tumor surveillance and promptly refer suspicious lesions to pediatric oncology.

Surveillance for Wilms tumor, liver tumors, and gonadoblastoma is recommended by the clinical-utility guidance, including affected males and symptomatic females. Exact ages and intervals were not supplied in the retrieved guideline excerpt; therefore, local overgrowth-syndrome protocols and genetics/oncology consultation should determine abdominal/renal ultrasound and alpha-fetoprotein schedules rather than relying on an uncited universal schedule. (vuillaume2019cugcforsimpsongolabibehmel pages 4-5)

No SGBS1-directed interventional clinical trial was identified. Multiple trials found by a GPC3 search concern GPC3-expressing cancers and use antibodies, imaging agents, CAR-T, or CAR-NK products. These aim to attack tumor cells expressing GPC3 and are not treatments for constitutional GPC3 deficiency; extrapolation to SGBS1 would be mechanistically inappropriate.

13. Prevention

Primary prevention through lifestyle modification or vaccination is impossible because SGBS1 is genetic. Effective reproductive-risk reduction requires genetic counseling, identification of the familial variant, and informed use of prenatal diagnosis or preimplantation genetic testing. Prenatal molecular diagnosis can be offered to known carriers. (vuillaume2019cugcforsimpsongolabibehmel pages 4-5, vuillaume2019cugcforsimpsongolabibehmel pages 5-6)

Secondary prevention consists of early molecular diagnosis, cascade testing, prenatal ultrasound in at-risk pregnancies, neonatal glucose and cardiopulmonary assessment, developmental screening, and tumor surveillance. Tertiary prevention comprises cardiac follow-up, timely surgery, rehabilitation, educational intervention, and surveillance intended to detect treatable tumors before symptoms or metastasis. There is no vaccine, chemoprophylaxis, or disease-specific public-health environmental intervention.

14. Other species and natural disease

No naturally occurring veterinary syndrome definitively equivalent to human SGBS1 was established in the retrieved literature. Accordingly, there is no recognized breed predisposition, veterinary transmission concern, or zoonotic potential.

GPC3 orthologs are evolutionarily conserved across vertebrates. Relevant experimental species include Mus musculus (NCBI Taxon 10090) and potentially zebrafish and other developmental models, but naturally occurring disease should be distinguished from engineered loss-of-function models.

15. Model organisms

Targeted Gpc3-null mice reproduce important elements of human SGBS1: developmental overgrowth, placentomegaly, renal dysplasia, accessory spleens, abnormal lung development, polydactyly, and perinatal death. These findings provide in-vivo evidence that GPC3 is an upstream regulator of embryonic growth and patterning and support Hedgehog-pathway dysregulation. (vuillaume2018mutationupdatefor pages 13-14)

Model limitations are substantial: murine lethality and anomaly frequencies do not precisely mirror human survival or expressivity; cognition and human educational outcomes are difficult to model; and the model does not establish quantitative human tumor risk. Cellular SGBS-derived preadipocyte lines are widely used in adipogenesis research, but their utility as a complete disease model is limited because an immortalized or selected cell line cannot represent multisystem embryogenesis.

Recent developments, 2023–2024, and evidence gaps

The recent literature has emphasized broader ascertainment rather than a new therapy: prenatal copy-number diagnoses, affected females, intrafamilial variability, atypical presentations, and adult diagnoses that can mimic acromegaly. A 2024 phenotype-spectrum and tumor-risk review and a 2024 disease review were identified by the search, but their full text was unavailable to the evidence extractor; numerical claims from those papers are therefore not reproduced without verification. This limitation is important because older tumor estimates are based on small, publication-biased series.

Priority research needs are: prospective international natural-history registries; genotype- and sex-stratified penetrance estimates; standardized tumor incidence and surveillance endpoints; systematic female-carrier cohorts; long-term adult cardiac and cancer outcomes; patient-reported quality-of-life measures; patient-derived organoids or iPSCs; tissue-resolved pathway profiling; and safe approaches to restoring appropriate GPC3 function during the relevant developmental window.

Key sources and abstract-level quotations

1. Vuillaume et al., “Mutation update for the GPC3 gene involved in Simpson-Golabi-Behmel syndrome and review of the literature.” Human Mutation. Published June 2018. DOI/URL: https://doi.org/10.1002/humu.23428. The retrieved evidence reports 57 previously published plus 29 new variants, yielding 86 distinct variants across 120 families, and describes GPC3 as a 70-kDa proteoglycan regulating WNT, Hedgehog, FGF, and BMP signaling. (vuillaume2018mutationupdatefor pages 1-2, vuillaume2018mutationupdatefor pages 13-14)

2. Vuillaume et al., “CUGC for Simpson-Golabi-Behmel syndrome (SGBS).” European Journal of Human Genetics. Published January 2019; 27:663–668. DOI/URL: https://doi.org/10.1038/s41431-019-0339-z. This is the principal retrieved clinical-utility source for testing, differential diagnosis, management, penetrance, and prognosis. (vuillaume2019cugcforsimpsongolabibehmel pages 2-4, vuillaume2019cugcforsimpsongolabibehmel pages 4-5, vuillaume2019cugcforsimpsongolabibehmel pages 1-2)

3. Foundational GPC3 discovery literature: Open Targets links the SGBS1–GPC3 association to PMID:8589713 and additional human genetic reports including PMID:10814714, PMID:9950367, PMID:16158429, PMID:17850639, and PMID:18203194. These database links provide primary-literature anchors for curation, although individual claims should be checked against each original article before assigning variant-level evidence. (OpenTargets Search: Simpson-Golabi-Behmel syndrome type 1-GPC3)

A directly verified quotation from a recent prenatal abstract is: “Simpson–Golabi–Behmel syndrome type 1 (SGBS1) is a rare X-linked recessive disorder characterized by pre- and postnatal overgrowth and a broad spectrum of anomalies including craniofacial dysmorphism, heart defects, renal, and genital anomalies.” Liu et al., Molecular Genetics & Genomic Medicine, published July 2021, DOI: https://doi.org/10.1002/mgg3.1750. This quotation is consistent with the independently retrieved mutation and clinical-utility evidence. (vuillaume2019cugcforsimpsongolabibehmel pages 1-2, vuillaume2018mutationupdatefor pages 1-2)

Evidence-quality note

Most clinical knowledge derives from case reports, small family series, and retrospective literature compilations. The genetic causation evidence is strong, but phenotype frequencies, female penetrance, tumor incidence, surveillance effectiveness, and adult prognosis remain low-certainty because population-based cohorts are absent. Assertions unsupported by the retrieved full text—particularly exact tumor percentages, universal surveillance intervals, and unverified ontology or ICD mappings—have deliberately been labeled uncertain rather than presented as established facts.

References

1. (vuillaume2019cugcforsimpsongolabibehmel pages 2-4): Marie-Laure Vuillaume, Marie-Pierre Moizard, Alessandra Baumer, Edouard Cottereau, Frédéric Brioude, Anita Rauch, and Annick Toutain. Cugc for simpson-golabi-behmel syndrome (sgbs). European Journal of Human Genetics, 27:663-668, Jan 2019. URL: https://doi.org/10.1038/s41431-019-0339-z, doi:10.1038/s41431-019-0339-z. This article has 11 citations and is from a domain leading peer-reviewed journal.

2. (vuillaume2019cugcforsimpsongolabibehmel pages 4-5): Marie-Laure Vuillaume, Marie-Pierre Moizard, Alessandra Baumer, Edouard Cottereau, Frédéric Brioude, Anita Rauch, and Annick Toutain. Cugc for simpson-golabi-behmel syndrome (sgbs). European Journal of Human Genetics, 27:663-668, Jan 2019. URL: https://doi.org/10.1038/s41431-019-0339-z, doi:10.1038/s41431-019-0339-z. This article has 11 citations and is from a domain leading peer-reviewed journal.

3. (vuillaume2019cugcforsimpsongolabibehmel pages 1-2): Marie-Laure Vuillaume, Marie-Pierre Moizard, Alessandra Baumer, Edouard Cottereau, Frédéric Brioude, Anita Rauch, and Annick Toutain. Cugc for simpson-golabi-behmel syndrome (sgbs). European Journal of Human Genetics, 27:663-668, Jan 2019. URL: https://doi.org/10.1038/s41431-019-0339-z, doi:10.1038/s41431-019-0339-z. This article has 11 citations and is from a domain leading peer-reviewed journal.

4. (OpenTargets Search: Simpson-Golabi-Behmel syndrome type 1-GPC3): Open Targets Query (Simpson-Golabi-Behmel syndrome type 1-GPC3, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

5. (vuillaume2018mutationupdatefor pages 13-14): Marie-Laure Vuillaume, Marie-Pierre Moizard, Sylvie Rossignol, Edouard Cottereau, Sandrine Vonwill, Jean-Luc Alessandri, Tiffany Busa, Estelle Colin, Marion Gérard, Fabienne Giuliano, Laetitia Lambert, Mathilde Lefevre, Udhaya Kotecha, Sheela Nampoothiri, Irène Netchine, Martine Raynaud, Frédéric Brioude, and Annick Toutain. Mutation update for the gpc3 gene involved in simpson‐golabi‐behmel syndrome and review of the literature. Human Mutation, 39:790-805, Jun 2018. URL: https://doi.org/10.1002/humu.23428, doi:10.1002/humu.23428. This article has 42 citations and is from a domain leading peer-reviewed journal.

6. (vuillaume2018mutationupdatefor pages 1-2): Marie-Laure Vuillaume, Marie-Pierre Moizard, Sylvie Rossignol, Edouard Cottereau, Sandrine Vonwill, Jean-Luc Alessandri, Tiffany Busa, Estelle Colin, Marion Gérard, Fabienne Giuliano, Laetitia Lambert, Mathilde Lefevre, Udhaya Kotecha, Sheela Nampoothiri, Irène Netchine, Martine Raynaud, Frédéric Brioude, and Annick Toutain. Mutation update for the gpc3 gene involved in simpson‐golabi‐behmel syndrome and review of the literature. Human Mutation, 39:790-805, Jun 2018. URL: https://doi.org/10.1002/humu.23428, doi:10.1002/humu.23428. This article has 42 citations and is from a domain leading peer-reviewed journal.

7. (vuillaume2019cugcforsimpsongolabibehmel pages 5-6): Marie-Laure Vuillaume, Marie-Pierre Moizard, Alessandra Baumer, Edouard Cottereau, Frédéric Brioude, Anita Rauch, and Annick Toutain. Cugc for simpson-golabi-behmel syndrome (sgbs). European Journal of Human Genetics, 27:663-668, Jan 2019. URL: https://doi.org/10.1038/s41431-019-0339-z, doi:10.1038/s41431-019-0339-z. This article has 11 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

• HP:0001524 (2 mentions) - HP does not contain this term

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0031225 (obsolete anchored component of membrane) (1 mention) - replaced by GO:0016020